Brokerages Set Eli Lilly and Company (NYSE:LLY) Target Price at $787.53

Eli Lilly and Company (NYSE:LLYGet Free Report) has received an average rating of “Moderate Buy” from the nineteen research firms that are presently covering the stock, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and sixteen have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $803.50.

Several research firms have recently issued reports on LLY. Citigroup upped their price objective on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Argus raised their price target on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research note on Tuesday, May 14th. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. JPMorgan Chase & Co. increased their price objective on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. Finally, Truist Financial lifted their target price on Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st.

Get Our Latest Report on Eli Lilly and Company

Eli Lilly and Company Stock Performance

NYSE LLY opened at $891.46 on Friday. The firm’s fifty day moving average price is $793.39 and its two-hundred day moving average price is $724.73. The stock has a market cap of $847.25 billion, a PE ratio of 131.29, a PEG ratio of 1.93 and a beta of 0.36. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. Eli Lilly and Company has a fifty-two week low of $434.34 and a fifty-two week high of $894.87.

Eli Lilly and Company (NYSE:LLYGet Free Report) last issued its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The business had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. Eli Lilly and Company’s quarterly revenue was up 26.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.62 EPS. On average, equities analysts expect that Eli Lilly and Company will post 13.76 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, June 10th. Shareholders of record on Thursday, May 16th were issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 0.58%. The ex-dividend date was Wednesday, May 15th. Eli Lilly and Company’s payout ratio is 76.58%.

Insider Activity

In other news, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the sale, the chief accounting officer now directly owns 7,130 shares in the company, valued at approximately $5,842,821.10. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In related news, major shareholder Lilly Endowment Inc sold 2,052 shares of the company’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $809.00, for a total value of $1,660,068.00. Following the sale, the insider now owns 98,554,195 shares in the company, valued at approximately $79,730,343,755. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Donald A. Zakrowski sold 750 shares of the stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the sale, the chief accounting officer now directly owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 762,804 shares of company stock worth $648,109,138. Company insiders own 0.13% of the company’s stock.

Hedge Funds Weigh In On Eli Lilly and Company

Hedge funds have recently bought and sold shares of the company. Lipe & Dalton bought a new position in Eli Lilly and Company in the 4th quarter valued at $26,000. Core Wealth Advisors Inc. boosted its holdings in shares of Eli Lilly and Company by 188.2% in the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after buying an additional 32 shares during the last quarter. Activest Wealth Management bought a new position in Eli Lilly and Company during the first quarter valued at about $39,000. Tidemark LLC purchased a new stake in Eli Lilly and Company during the fourth quarter worth about $29,000. Finally, Redmont Wealth Advisors LLC bought a new stake in Eli Lilly and Company in the first quarter worth about $40,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

About Eli Lilly and Company

(Get Free Report

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

See Also

Analyst Recommendations for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.